Lithium Hydroxide → (R)-2-[4-((S)-2-carboxy-pyrrolidin-1-yl)-piperidin-1-yl]-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

HRID 1864624Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1864624
[Li+].[OH-].[O:3]=[C:4]1[N:10]([CH:11]2[CH2:16][CH2:15][N:14]([C:17]([O:19][C@H:20]([CH2:38][C:39]3[CH:48]=[C:47]([CH3:49])[C:42]4[NH:43][C:44](=[O:46])[O:45][C:41]=4[CH:40]=3)[C:21]([N:23]3[CH2:28][CH2:27][CH:26]([N:29]4[CH2:33][CH2:32][CH2:31][C@H:30]4[C:34]([O:36]C)=[O:35])[CH2:25][CH2:24]3)=[O:22])=[O:18])[CH2:13][CH2:12]2)[CH2:9][CH2:8][C:7]2[CH:50]=[CH:51][CH:52]=[CH:53][C:6]=2[NH:5]1>O.C1COCC1>[O:3]=[C:4]1[N:10]([CH:11]2[CH2:12][CH2:13][N:14]([C:17]([O:19][C@H:20]([CH2:38][C:39]3[CH:48]=[C:47]([CH3:49])[C:42]4[NH:43][C:44](=[O:46])[O:45][C:41]=4[CH:40]=3)[C:21]([N:23]3[CH2:24][CH2:25][CH:26]([N:29]4[CH2:33][CH2:32][CH2:31][C@H:30]4[C:34]([OH:36])=[O:35])[CH2:27][CH2:28]3)=[O:22])=[O:18])[CH2:15][CH2:16]2)[CH2:9][CH2:8][C:7]2[CH:50]=[CH:51][CH:52]=[CH:53][C:6]=2[NH:5]1

Komponenten

5

Versuchsvorschrift

A solution of 17 mg (0.71 mmol) LiOH in 3 mL water was added to a solution of 200 mg (0.29 mmol) (R)-2-[4-((S)-2-methoxycarbonyl-pyrrolidin-1-yl)-piperidin-1-yl]-1-(4-methyl-2-oxo-2,3-dihydro-benzoxazol-6-ylmethyl)-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate in 9 mL THF and the reaction mixture was stirred for 66 h at RT. The solvents were eliminated in a nitrogen current and the residue was purified by HPLC. The fractions containing the product were combined and lyophilised.

Aufarbeitung

  1. customthe residue was purified by HPLC
  2. additionThe fractions containing the product

Quellen und Nachweise

ORD-Eintrag
ord-7ac4ebe8f91543099777d56481c93fe7
Quelldatensatz
uspto-grants-2009_12
Patentnummer
US07625886B2

Notizen zur Reaktion

Wird geladen…